Barclays PLC Organon & Co. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Organon & Co. stock. As of the latest transaction made, Barclays PLC holds 119,483 shares of OGN stock, worth $1.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

119,483

Previous 119,483 -0.0%

Holding current value

$1.76 Million

Previous $2.29 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$18.65 - $23.03 $1.57 Million - $1.94 Million	84,136 Added 238.03%	119,483 $2.29 Million
Q2 2024 Aug 14, 2024	SELL	$17.45 - $21.96 $4.05 Million - $5.1 Million	-232,205 Reduced 86.79%	35,347 $731,000
Q1 2024 May 15, 2024	BUY	$13.78 - $18.8 $648,831 - $885,198	47,085 Added 21.36%	267,552 $5.03 Million
Q4 2023 Feb 15, 2024	SELL	$10.95 - $17.32 $2.65 Million - $4.19 Million	-241,647 Reduced 52.29%	220,467 $3.18 Million
Q3 2023 Nov 07, 2023	BUY	$16.59 - $23.77 $2.19 Million - $3.13 Million	131,725 Added 39.87%	462,114 $8.02 Million
Q2 2023 Aug 03, 2023	BUY	$19.27 - $24.63 $4.82 Million - $6.16 Million	250,072 Added 311.36%	330,389 $6.87 Million
Q1 2023 May 04, 2023	SELL	$21.42 - $32.08 $2.24 Million - $3.35 Million	-104,496 Reduced 56.54%	80,317 $1.89 Million
Q4 2022 Feb 13, 2023	BUY	$23.31 - $28.61 $325,011 - $398,909	13,943 Added 8.16%	184,813 $5.16 Million
Q3 2022 Nov 03, 2022	BUY	$23.4 - $34.25 $684,707 - $1 Million	29,261 Added 20.66%	170,870 $4 Million
Q2 2022 Aug 12, 2022	SELL	$31.66 - $38.9 $4.26 Million - $5.23 Million	-134,559 Reduced 48.72%	141,609 $4.78 Million
Q1 2022 May 16, 2022	BUY	$30.45 - $39.36 $8.41 Million - $10.9 Million	276,168 New	276,168 $9.65 Million

Others Institutions Holding OGN

# of Institutions

791

Shares Held

193M

Call Options Held

1.71M

Put Options Held

865K

View Full List

About Organon & Co.

Ticker OGN
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 254,330,000
Market Cap $3.75B
Description
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...

More about OGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account